Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
Authors
Keywords
-
Journal
PEDIATRIC BLOOD & CANCER
Volume 60, Issue 5, Pages 791-798
Publisher
Wiley
Online
2012-09-21
DOI
10.1002/pbc.24301
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.
- (2017) G. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.
- (2017) S. E. Coutre et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
- (2015) Oncotarget
- Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
- (2011) J. Zhang et al. BLOOD
- Targeting mTOR globally in cancer: Thinking beyond rapamycin
- (2011) Boris Shor et al. CELL CYCLE
- Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways
- (2011) N. Shukla et al. CLINICAL CANCER RESEARCH
- Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
- (2011) Lova Segerström et al. INTERNATIONAL JOURNAL OF CANCER
- A Sensitized RNA Interference Screen Identifies a Novel Role for the PI3K p110 Isoform in Medulloblastoma Cell Proliferation and Chemoresistance
- (2011) A. S. Guerreiro et al. MOLECULAR CANCER RESEARCH
- Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
- (2011) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
- (2010) P. J. Houghton et al. MOLECULAR CANCER THERAPEUTICS
- PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis
- (2010) A Bender et al. ONCOGENE
- National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing
- (2010) Min H. Kang et al. PEDIATRIC BLOOD & CANCER
- Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program
- (2010) Hernan Carol et al. PEDIATRIC BLOOD & CANCER
- Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
- (2010) S. Buonamici et al. Science Translational Medicine
- Targeting the Phosphoinositide 3-Kinase Isoform p110 Impairs Growth and Survival in Neuroblastoma Cells
- (2008) D. Boller et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K p110 Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration
- (2008) A. S. Guerreiro et al. CLINICAL CANCER RESEARCH
- The role of PTEN signaling perturbations in cancer and in targeted therapy
- (2008) M Keniry et al. ONCOGENE
- Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started